New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CAT;IQNT;GRMN;JCP;JNJ;KRC;NKTR;STRA;VRTX;VNO;BMY;PBR;HES From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>
May 14, 2015
07:11 EDTJCPOptions expected to be active
Subscribe for More Information
06:52 EDTJCPJ.C. Penney target upped to $15 after Q1 results at Piper Jaffray
Subscribe for More Information
May 13, 2015
17:50 EDTJNJPharmacyclics to showcase new 'promising' Imbruvica data at ASCO
Pharmacyclics announced that ibrutinib, also known as Imbruvica, single-agent and combination data will be featured in seven oral and poster sessions at the 51st American Society of Clinical Oncology, ASCO, Annual Meeting being held May 29-June 2 in Chicago, IL. According to a statement from ASCO, Imbruvica data will also be included in the official press program during the meeting for the second time in two years. Imbruvica is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a Johnson & Johnson (JNJ) subsidiary. Data being presented include, among others, an oral presentation from the Phase III HELIOS study of ibrutinib in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia, a poster presentation of ibrutinib in steroid-dependent or refractory chronic graft-versus-host-disease as well as a dose adherence analysis of ibrutinib 420 mg administered to previously treated CLL patients. "We look forward to sharing promising data at this year's ASCO that examines the use of Imbruvica across a broad range of hematologic disease settings from our clinical studies," said Danelle James, M.D., M.S., Head of Oncology at Pharmacyclics.
16:39 EDTJCPJ.C. Penney gross margin helped by penetration of private brands
Subscribe for More Information
16:34 EDTJCPJ.C. Penney saw slowdown in late April versus its expectations
Subscribe for More Information
16:28 EDTJCPJ.C. Penney sees FY15 free cash flow breakeven
Subscribe for More Information
16:26 EDTJCPJ.C. Penney reports Q1 gross margin 36.4%
Subscribe for More Information
16:13 EDTJCPJ.C. Penney narrows FY15 SSS view to up 4%-5% from up 3%-5%
Subscribe for More Information
16:09 EDTJCPJ.C. Penney reports Q1 EPS (57c), consensus (77c)
Subscribe for More Information
15:15 EDTJCPJ.C. Penney May 9 straddle priced for 8.2% movement into Q1
Subscribe for More Information
15:04 EDTJCPNotable companies reporting after market close
Subscribe for More Information
13:12 EDTBMYSen. Sanders urges VA to break patents on Gilead hepatitis C drugs
Subscribe for More Information
12:54 EDTJCPEarnings Watch: J.C. Penney sees Q1 SSS up 3.5%-4.5%
J.C. Penney (JCP) is scheduled to report first quarter earnings after the market close on Wednesday, May 13, with a conference call scheduled for 4:30 pm ET. J.C. Penney operates about 1,100 retail stores and jcp.com. EXPECTATIONS: Analysts are looking for a loss per share of (77c) on revenue of $2.87B, according to First Call. The consensus range for EPS is (96c)-(61c) on revenue of $2.78B-$2.92B. LAST QUARTER: J.C. Penney reported fourth adjusted earnings per share of breakeven against estimates for 11c, on revenue of $3.89B against estimates for $3.87B. Comparable store sales were up 4.4%. The company forecast fiscal year 2015 SSS up 3%-5% and said it expected gross margin to improve 50 to 100 basis points versus 2014 and free cash flow to be flat. On its Q4 earnings conference call, the company said that it expected Q1 sales to be impacted less than 1% due to the West Coast port slowdown. NEWS: On March 17, AdAge said Chief Marketing Officer Debra Berman would leave the company immediately. Later that day, Bloomberg reported that General Cousnel Janet Dhillon would also leave the company, which was confirmed by J.C. Penney on March 20. On April 28, J.C. Penney appointed Mary Beth West as executive vice president and Chief Customer & Marketing Officer, effective June 1. In an April regulatory filing, J.C. Penney said it became aware that a senior company official "inadvertently sent an e-mail communication to a securities analyst that contained non-public information regarding the company’s comparable store sales results for Q1 to date, which are approximately 6%." The company said it expects Q1 SSS up 3.5%-4.5%, which takes into account the shift of Easter into March. The retailer said it would introduce Sephora to 25 additional stores starting on May 1. In April, New York Attorney General Eric Schneiderman sent letters warning J.C. Penney and other retailers that he believes the chains are using on-call scheduling and that such practices may be in violation of New York laws. STREET RESEARCH: Following the release of J.C. Penney's Q4 results, Deutsche Bank said J.C. Penney remained a "show me story" until liquidity is improved. Craig-Hallum said J.C. Penney's 2015 gross margin outlook supports its view the company's 2017 financial targets are "unattainable." In March, JPMorgan raised its price target for the retailer to $10 from $8 and said management expressed confidence in the company’s ability to reach its 2017 EBITDA target of $1.2B. Baird said J.C. Penney's business is on "more stable footing," but believes meaningful free cash flow growth will be challenging. PRICE ACTION: Over the last three months, J.C. Penney shares are up over 7.45%. In early afternoon trading ahead of Wednesday's Q1 report, J. C. Penney is down 2.5% to $8.66.
07:19 EDTVRTXVertex shares should have upward momentum in near-term, says JMP Securities
Subscribe for More Information
May 12, 2015
17:54 EDTVRTXOn The Fly: After Hours Movers
Subscribe for More Information
16:49 EDTVRTXVertex resumes after-hours trading, shares up 5.6% to $131.00
Subscribe for More Information
16:20 EDTVRTXVertex to resume trading at 14:45
16:19 EDTVRTXVertex confirms FDA panel voted 12-to-1 to recommend approval of Orkambi
Subscribe for More Information
16:16 EDTVRTXVertex confirms FDA panel voted 12-to-1 to recommend approval of Orkambi
16:16 EDTVRTXPiper Jaffray remains confident in approval for Vertex
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use